ClinicalTrials.gg
RecruitingNCT06675604LEOPARD TVDCSUpdated Jul 29, 2026

LEOPARD Training and Validation Data Collection Study

An observational study in Decompensated Liver Cirrhosis, Primary Biliary Cholangitis and Primary Sclerosing Cholangitis, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 53 sites in 7 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
4,500
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 25 studies in Liver Cirrhosis, Biliary with a site in Italy — 5 open to participants now, 11 under way, 4 of them phase 3. Liver Cirrhosis, Biliary · Italy.

Started
2025
the only one that year
Observational
5 of 25
3 open now
Primary completion
2028-03
later than 4 of 10 live
Registered
21st of 25
by date
Lead sponsor
2 of 25
Assistance Publique - Hôpitaux de Paris

Among the 25 studies in Liver Cirrhosis, Biliary with a site in Italy, this one is the only one that started in 2025, is one of 5 observational ones, reaches primary completion later than 4 of the 10 other live ones, and was the 21st registered.

Liver Cirrhosis, Biliary

214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.

Browse Liver Cirrhosis, Biliary studies →

Open to participants now

5 of the 25 studies in Liver Cirrhosis, Biliary with a site in Italy are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Liver Cirrhosis, Biliary with a site in Italy, or all of them as a file.
02

Study summary

Intro:

The present clinical research protocol is part of the LEOPARD European project (Grant n° 101080964 Horizon Europe) which aims to design and validate new predictive models of mortality among liver transplantation (LT) candidates. MELD based-liver graft allocation systems have become increasingly inaccurate over the last decade to predict mortality/dropout of liver transplantation (LT) candidates on the waitlist (WL). Wide disparities in mortality/dropout on the WL also exist across European countries, ranging from 5 to 30% according to transplantation indications and countries. In this setting, the European Commission- Horizon Europe funded-LEOPARD project intends to design new, 2nd generation, AI-machine learning-based predictive models of delisting in LT candidates, to better serve on time patients with the highest risk of dropout on the WL and to improve equity of access to LT across Europe.

Hypothesis/Objective:

The scientific justification of the LEOPARD TVDCS is therefore to collect a large set of data in liver transplantation candidates listed in Europe a) to design and b) to validate LEOPARD 2nd generation AI-based predictive models of mortality/dropout The primary objective is to develop new predictive models of mortality/drop out on the waitlist in patients with decompensated cirrhosis, or other end-stage chronic liver diseases, and in patients listed for Hepato-cellular carcinoma (HCC).

Method:

Longitudinal multicenter prospective health care data collection cohort study in 2 sets : Training/development set : Prospective health care data collection in 3,000 patients listed in 50 centres across 7 countries and Validation set: Prospective health care data collection in 1,500 subsequent patients listed in the same 50 centres.

03

Conditions studied

  • Decompensated Liver Cirrhosis
  • Primary Biliary Cholangitis
  • Primary Sclerosing Cholangitis
  • Hepato-cellular Carcinoma

Keywords

  • Liver transplantation
  • predictive models
  • data collection cohort
  • liver transplantation candidates
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults patients listed for :

  • Decompensated cirrhosis as primary diagnosis, irrespective of liver disease etiology (subset 1)
  • Other chronic end-stage liver diseases requiring LT, to be listed under a MELD-based allocation system (examples: primary biliary cholangitis, primary sclerosing cholangitis etc…) (subset 2)
  • Hepato-cellular carcinoma as primary diagnosis, whatever the etiology of the underlying liver disease with or without underlying cirrhosis (subset 3)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult [age 18;70] patients listed for:

    • decompensated cirrhosis as primary diagnosis, irrespective of liver disease etiology (subset 1) OR
    • other chronic end-stage liver diseases requiring LT, to be listed under a MELD-based allocation system (examples: primary biliary cholangitis, primary sclerosing cholangitis etc…) (subset 2) OR
    • HCC* as primary diagnosis, whatever the etiology of the underlying liver disease with or without underlying cirrhosis (subset 3). (HCC diagnosed on Barcelona/EASL criteria or proven. HCC meeting or not Milan criteria, as per center practice.)
  • Patients registered on national waiting lists under the MELD offering schemes, regardless of extra MELD points and MELD exceptions are affected or not.
  • Patient (or trusted person, family member or close relation, if the patient is unable to be informed) who has been informed and did not express opposition to data collection

(*Of note, enrolment of patients with T1 tumors (1 single tumor \< 2 cm diameter) not amenable to loco-regional therapies because of decompensation, and prioritized under the MELD system, will be allowed in Subset 1.)

Exclusion criteria

Exclusion Criteria:

  • Tumor vascular invasion (portal or hepatic veins) evidenced by imaging at pre transplantation work-up, including portal vein thrombosis stage 1
  • Extra-hepatic of HCC, as assessed by sectional imaging, functional imaging (18 FDG PET CT/MRI) or proven
  • Patients who are under safeguard of justice or tutorship or curatorship
  • Patient on AME (state medical aid)
  • Participation to LEOPARD PVC 1 study of WP2
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
4,500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Subset 1

    Decompensated cirrhosis as primary diagnosis, irrespective of liver disease etiology

  • Subset 2

    Other chronic end-stage liver diseases requiring LT, to be listed under a MELD-based allocation system (examples: primary biliary cholangitis, primary sclerosing cholangitis etc…)

  • Subset 3

    Hepato-cellular carcinoma as primary diagnosis, whatever the etiology of the underlying liver disease with or without underlying cirrhosis

06

What researchers measure

Primary outcomes

  1. Clinical primary endpoint considered as the event of interest to be predicted will be a composite of number of participants with mortality or drop out for being too sick on transplantation waiting list.

    * 3-month mortality/dropout for being too sick after listing in subsets 1 and 2 * 12-month mortality/dropout for being too sick (tumor progression) after listing in subset 3

    Time frame: 3 months after listing in subsets 1 & 2 ; 12 months after listing in subset3

Secondary outcomes

  1. Number of participants with 6- and 9-month pre LT mortality dropout for being too sick (all subsets)

    Mortality (all subsets)

    Time frame: 6 and 9 months after listing

  2. Causes of death/drop-out for being too sick

    Causes of death/drop-out (all subsets)

    Time frame: From date of inclusion until date of death from any cause or date of drop-out for being too sick, whichever came first, assessed up to 12 months

  3. Incidence of delisting for patient's decision or clinical improvement

    delisting for patient's decision or clinical improvement

    Time frame: From date of inclusion until date of delisting for patient's decision or clinical improvement, assessed up to 12 months

  4. Time from listing to death/dropout

    Duration from listing to death/dropout (days)

    Time frame: From date of listing until date of death from any cause or date of drop-out for being too sick, whichever came first, assessed up to 12 months

  5. Time to transplantation

    Duration from listing to transplantation (days)

    Time frame: From date of listing until date of transplantation, assessed up to 12 months

  6. Number of participants with 6-month and 12 month post LT survival in subsets 1 to 3

    Survival in Training cohort subsets 1 to 3

    Time frame: 6 months and 12 months after liver transplantation

  7. Number of participants with 12-month HCC recurrence in subset 3

    HCC recurrence in Training cohort subset 3

    Time frame: 12 months after liver transplantation

  8. Number of participants with 6-month post-LT survival (all subsets)

    Survival in Validation cohort all subsets

    Time frame: 6 month after liver transplantation

  9. 6-month transplant benefit (all subsets)

    Relevant comorbidities (diabetes, hypertension, stroke, coronary disease, cancers, alcohol and tobacco consumption) in Validation cohort all subsets

    Time frame: 6 months after liver transplantation

07

Study locations

53 of 53 sites recruiting
  • Universitätsklinik für Allgemeinchirurgie, Klinische Abteilung für Transplantation
    Vienna, Austria
    Recruiting
    • Gabriela Berlakovich, MD-PHD · Contact
  • Hôpital Erasme Université Libre de Bruxelles
    Brussels, Belgium
    Recruiting
    • Thierry Gustot, MD-PHD · Contact
  • Department of Gastroenterology and Hepatology Universitair Ziekenhuis Gent
    Ghent, Belgium
    Recruiting
    • Hasan Eker, MD-PHD · Contact
  • Cliniques Universitaires Saint-Luc (UCLouvain)
    Leuven, Belgium
    Recruiting
    • Géraldine Dahlqvist, MD-PHD · Contact
  • UZ Leuven
    Leuven, Belgium
    Recruiting
    • Jef Verbeek, MD-PHD · Contact
  • CHU Liège
    Liège, Belgium
    Recruiting
    • Olivier Detry, MD-PHD · Contact
  • CHU Jean Minjoz Besançon, Department of Hepatology
    Besançon, 25000, France
    Recruiting
  • CHU Trousseau Tours, Department of Hepatology
    Chambray-lès-Tours, 37170, France
    Recruiting
  • CHU Beaujon, Department of Hepatology
    Clichy, 92110, France
    Recruiting
  • Hospital Henri Mondor, Department of Hepatology
    Créteil, 94010, France
    Recruiting
  • CHU Dijon, Department of Hepatology
    Dijon, 21069, France
    Recruiting
  • CHRU Huriez Lille, Department of Hepatology
    Lille, 59000, France
    Recruiting
  • CHU Lyon Croix Rousse, Department of Hepatology
    Lyon, 69004, France
    Recruiting
  • CHU La Timone AP-HM, Department of Hepatology
    Marseille, 13005, France
    Recruiting
  • CHRU Montpellier Saint Eloi, Department of Hepatology
    Montpellier, 34295, France
    Recruiting
  • CHU L'Archet Nice, Department of Hepatology
    Nice, 06000, France
    Recruiting
  • CHU La Pitié Salpêtrière, Department of Hepatology
    Paris, 75013, France
    Recruiting
  • CHU Bordeaux Haut Levêque, Department of Hepatology
    Pessac, 33604, France
    Recruiting
  • CHU Pontchaillou Rennes, Department of Hepatology
    Rennes, 35033, France
    Recruiting
  • CHRU Strasbourg, Chirurgie Hepato-bilio-pancreatique et transplantation hepatique Department
    Strasbourg, 67000, France
    Recruiting
  • CHU Purpan Toulouse, Department of Hepatology
    Toulouse, 31059, France
    Recruiting
  • CHU Paul Brousse, Department of Hepatology
    Villejuif, 94800, France
    Recruiting
  • Department for General, Visceral, Pediatric and Transplant Surgery, Universitätsklinikum Aachen
    Aachen, Germany
    Recruiting
    • Thomas Vogel, MD-PHD · Contact
  • Charité - Universitätsmedizin Berlin
    Berlin, Germany
    Recruiting
    • Nathanael Raschzok, MD-PHD · Contact
  • Gastroenterology, Hepatology, Infectious Diseases and Endocrinology (GHIE) Medizinische Hochschule Hannover
    Hanover, Germany
    Recruiting
    • Richard Taubert, MD-PHD · Contact
  • Universitätsklinikum Jena
    Jena, Germany
    Recruiting
    • Falk Rauchfuss, MD-PHD · Contact
  • Universitätsklinikum Schleswig - Holstein | UKSH · Transplantation Medicine
    Kiel, Germany
    Recruiting
    • Felix Braun, MD-PHD · Contact
  • Universität Leipzig
    Leipzig, Germany
    Recruiting
    • Thomas Berg, MD-PHD · Contact
  • Klinik für Allgemein-, Viszeral- und Transplantationschirurgie, Universitätsklinikum Münster
    Münster, Germany
    Recruiting
    • Andreas Pascher, MD-PHD · Contact
  • Klinik für Allgemeine, Viszeral- und Transplantationschirurgie, Universitätsklinikum Tübingen
    Tübingen, Germany
    Recruiting
    • Silvio Nadalin, MD-PHD · Contact
  • Universitätsklinikum Würzburg
    Würzburg, Germany
    Recruiting
    • Johan Lock, MD-PHD · Contact
  • Università Politecnica delle Marche
    Ancona, Italy
    Recruiting
    • Marco Vivarelli, MD · Contact
  • Aou Policlinico di Bari
    Bari, Italy
    Recruiting
    • Francesco Tandoi, MD-PHD · Contact
  • Hepatobiliary Surgery and Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna
    Bologna, Italy
    Recruiting
    • Matteo Cescon, MD · Contact
  • Ospedale Policlinico San Martino
    Genova, Italy
    Recruiting
    • Paolo Montanelli, MD · Contact
  • Division of General Surgery & Abdominal Transplantation, Asst Grande Ospedale Metropolitano Niguarda
    Milan, Italy
    Recruiting
    • Andrea Lauterio, MD · Contact
  • Fondazione IRCCS Istituto Nazionale dei Tumori
    Milan, Italy
    Recruiting
    • Marco Bongini, MD · Contact
  • Hepato-Pancreato-Biliary Surgery and Liver Transplantation, Azienda Ospedaliero Universitaria Policlinico di Modena
    Modena, Italy
    Recruiting
    • Fabrizio Di Benedetto, MD-PHD · Contact
  • Azienda Ospedaliera di Rilievo Nazionale A. Cardarelli
    Naples, Italy
    Recruiting
    • Alfonso Galeota Lanza, MD · Contact
  • Azienda Ospedale - Università Padova
    Padova, Italy
    Recruiting
    • Umberto Cillo, MD-PHD · Contact
  • Gastroenterology department, Istituto Mediterraneo per i Trapianti Ismett IRCCS
    Palermo, Italy
    Recruiting
    • Salvo Gruttadauria, MD-PHD · Contact
  • Hepatobiliary Surgery and Liver Transplantation, Azienda Ospedaliero Universitaria Pisana (Via Paradisa)
    Pisa, Italy
    Recruiting
    • Davide Ghinolfi, MD-PHD · Contact
  • Azienda Ospedaliero Universitaria Policlinico Umberto I di Roma
    Roma, Italy
    Recruiting
    • Fabio Melandro, MD · Contact
  • Hospital tor Vergata Roma
    Roma, Italy
    Recruiting
    • Tommaso Maria Manzia, MD · Contact
  • Azienda Ospedaliera San Camillo-Forlanini
    Rome, Italy
    Recruiting
    • Giuseppe Maria Ettorre, MD · Contact
  • Dipartimento di chirurgia generale e specialistica e dei trapianti, Università degli Studi di Torino
    Torino, Italy
    Recruiting
    • Torino Romagnoli, MD-PHD · Contact
  • Università Degli Studi di Udine
    Udine, Italy
    Recruiting
    • Umberto Baccarani, MD · Contact
  • Liver Transplant Unit, Surgery and Oncology, University of Verona
    Verona, Italy
    Recruiting
    • Amedeo Carraro, MD · Contact
  • Center for Liver Tumors Leiden of the Leiden University Medical Center (LUMC)
    Leiden, Netherlands
    Recruiting
    • Minneke Coenraad, MD-PHD · Contact
  • Gastroenterology and Hepatology, Rotterdam Erasmus Medical Center
    Rotterdam, Netherlands
    Recruiting
    • Caroline Den Hoed, MD · Contact
  • Department of General, Visceral and Transplantation Surgery, Hospital Universitario Virgen de La Arrixaca
    Murcia, Spain
    Recruiting
    • Victor Lopez, MD · Contact
  • Hospital Universitario Virgen del Rocío
    Seville, Spain
    Recruiting
    • Miguel Angel Gomez Bravo, MD · Contact
  • Hospital General Universitari València
    Valencia, Spain
    Recruiting
    • Marina Berenguer, MD-PHD · Contact
08

References and documents

Individual participant data

Plan to share: No — IPD will not be shared. Datas are own by Assistance Publique-Hôpitaux de Paris (AP-HP), please contact sponsor for further information.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for Mar 2028, 37 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2024
First posted
Nov 5, 2024
StartActual
Feb 4, 2025
Primary completionEst.
Mar 2028
CompletionEst.
Feb 4, 2029
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06675604
Collaborators
European Society for Organ Transplantation (ESOT)-European Liver and Intestine Transplant Association (ELITA)ELITA, University of Luxembourg, Italian National Transplant Centre (CNT), Hospital Universitario La Fe
Responsible party
Sponsor
First posted
Nov 5, 2024
Start date
Feb 4, 2025
Primary completion
Mar 2028 (estimated)
Completion
Feb 4, 2029 (estimated)
Last update
Jul 29, 2026

Study contacts

Christophe DUVOUX, MD-PHD
Contact
christophe.duvoux@aphp.fr
01 49 81 23 25 ext. +33
Nihel BERREBEH, Project Manager
Contact
nihel.berrebeh@aphp.fr
01 40 27 46 20 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion